|
Dr. Whitcomb joined Parke-Davis in 1992 where he served initially as Vice President in the Clinical Research Department and subsequently as a Vice President in the Drug Development group. His areas of responsibility included the development and approval of products for women's healthcare, FemPatch and Femhrt, and the diabetes drug Rezulin as well as oversight of earlier stage compounds for diabetic neuropathy and osteoporosis. Dr. Whitcomb is Chief Medical Officer at QuatRx Pharmaceuticals, a pharmaceutical company focusing on clinical development in the areas of endocrine and metabolic, cardiovascular and CNS. He received his M.D. from the University of Kansas. Prior to his tenure at Parke-Davis he was an Assistant Professor of Medicine at Harvard Medical School. Dr. Whitcomb was elected to the Board of Directors in November of 2001.
| 